Found this article...OUCH!!! Inovio CEO Preps Retail Investors for Drug Study Failure
By: Adam Feuerstein
Inovio Pharmaceuticals (INO) CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?
The red flags flying over Inovio are there for any clear-eyed investor to see:
Inovio pushed through shareholder vote approving a 1-for-4 reverse stock split on May 23, which went into effect on June 5. Why the need for a reverse stock split? Kim explained:
Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.
Interesting spin. Drug companies in leadership positions aren't generally valued with stock prices in the $2 range. More typically, terminally depressed stock prices -- like Inovio's -- are the direct result of management incompetence and/or drug development setbacks and failures. Innovio is very good at issuing press releases and promoting its stock to retail investors, but its track record of developing DNA vaccines is abysmal.
Actually the company fundamentals are OK for a small biotech. They have some rev's, no debt, low OS and some cash...so this tells me it is running on a good engine(management). They have NO PRODUCTS that i could find, so their Rev's are probably milestone payments from their partner. But here's your problem...they only have 2 Phase 2 trials and a ton of Phase 1's. So you are talking from 3-5+ years ( if you are lucky) away from anything close to a NDA. So for this it is already $10+ per share...to me this is somewhat over valued for a small biotech with no phase 3 trials. This is exactly the type of stock that could be $2 if you blink your eyes or $ 15 if it gets bought out. So its all about the technology, if you believe in the technology and the Partner Roche, then you will hang in there but it could be a long bumpy ride. Personally, I wouldn't hold your breath for a buy out. But I would love to see the results of any of the Phase 2 trials (When do you expect those to be completed ? ). Will the technology be validated?
One more little negative...there are a ton of bag holders over $10, ...they want their money back...so that will kill most big rally's - any major pop could be meet with a FULL FIB RETRACEMENT of 61% or even more. Keep that in mind.
And the CFO, Dr. Jacqualyn A. Fouse Ph.D., 53 Chief Financial Officer and Exec. VP make $4.47 MILLION...WOW !
Love CPHD...but tends to sell off and disappoint the Q repts. A lot of times with major dumps. But you trading longs know that, you guys always short prior to Q-rept. Thats a good one, letting the newbies do the heavy lifting. Oh you guys know all this. Possible sub $40 by next week, we'll see. The thing with CPHD is it has a great following, tends to resist the "bad news " that occurs from time to time. But the strong following tends to over value the stock.
OT-Guys take this weeks biotech sector sell off to look at ACAD. Has a Billion Dollar Drug-One of a Kind- First in its class drug - with the - only drug indication for Parkinson's Disease Psychosis. Affects about 40% of the 1 million Parkinson's patients in the USA - new drug application (NDA) just around the corner. Lots of cash and No debt. And no partner YET. And get this...the FDA already has looked at the phase 3 trial results and given it a thumbs up to proceed to the NDA.
You are still dancing around my easy question...SALARY of 415 K....is it absolutely nuts or appropriate. Yes or No. My post, my topic.
OK I will respect your opinion since I have never followed CELG and really not interested in defending his rep at this point only the fact that his salary is not way out of line. But I would say you might give him a chance at this new point in his career.
Interesting how I mention idiots and you reply...whatever.
Now I am a little confused, because you wrote this..." These salary & options are absolutely nuts." So which is it ? So now you feel the salary is appropriate? Is the salary appropriate or is it " ...absolutely nuts. " ...YES OR NO ?
This is why some here hate me & always give me a thumbs down...because i point out what a DIMWIT they are. I wouldn't have it any other way.
"" Malaysia Airlines has said 295 people were aboard the flight from Amsterdam to Kuala Lumpur.""
Geez, some of you guys a complete IDIOTS....the new CFO's pay is appropriate. Look at MNKD...with a MK not exactly double of ACAD ....CFO who is a CPA by the way, Mr. Matthew J. Pfeffer CPA, 56
Chief Financial Officer, Principal Accounting Officer and Corp. VP $ 700.00K. And some of you here are whining about the new CFO ( with 20 years of executive-level experience in the pharmaceutical industry ) pay of $415 K. THATS CHEAP !!! what a bargin!
By the way ignore all the jolly short morons...just hit the ignore button. They hate being ignored.
The IBB is a Biotech MF. Since the Fed made a broad generalization about the Biotech sector, then really we are talking about the IBB. Its down and there is no sign of reverse at this time. ACAD will tend to be more volatile than the IBB, i.ei higher Beta, but there is a correlation. ACAD tends to follow the IBB, but with a higher Beta. ie more extreme moves. This may help identify a reverse.